Novartis Looks Appealing, Based on Drug Pipeline and Planned Spinoff

Text size These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the vi...

Opinion: Value has beaten growth by a huge margin — these are now top investment newsletters’ best value-stock picks

(Note: The dividend-yield column at the bottom of this story has been corrected. The correct yields are now shown.) Value will be especially valuable in 2022. I’m referring to the latest round in valu...